Rare disease workshop focuses on patient-centered drug development
EveryLife event explored ways to improve treatment reviews
Written by |
EveryLife Foundation for Rare Diseases’ 15th Scientific Workshop recently brought together leaders from the rare disease patient, scientific, government, and biopharmaceutical communities to discuss practical, patient-centered solutions for developing therapies for rare diseases amid evolving FDA pathways and programs.
Titled, “Making What Matters Count: Advancing Patient-Centered Rare Disease Therapy Development Methodologies, Tools, and Knowledge Management,” the event was held on May 12 in Washington, D.C.
EveryLife Foundation said it will synthesize the workshop’s key findings and recommendations in the coming weeks to support its policy and advocacy work, with the goal of advancing a more consistent, transparent, and patient-centered framework for rare disease therapy development.
Event aims to turn patient input into action
“Ensuring that patient experience is meaningfully and consistently integrated into therapy development requires not just policy changes, but alignment, coordination, and actionable tools,” Jamie Sullivan, EveryLife Foundation’s senior vice president of policy and advocacy, said in a press release. “This year’s discussion was designed to help us continue to identify concrete solutions that can be implemented across the ecosystem. We are grateful to everyone who attended [the] workshop, and we appreciate the productive conversations.”
Over the past two decades, there have been significant advancements in U.S. Food and Drug Administration (FDA) regulatory pathways and programs for rare diseases, which are conditions that affect fewer than 200,000 people in the U.S., including aromatic L-amino acid decarboxylase (AADC) deficiency.
Longstanding programs and pathways, such as Orphan Drug Designation, which provides incentives to companies developing treatments for rare diseases, and accelerated approval, have helped lay the foundation for these advancements.
Building on this progress, the FDA has launched several programs and frameworks in recent years. These include the START Pilot Program, which gives selected rare disease therapy developers more frequent FDA advice on issues such as clinical study design; the Rare Disease Evidence Principles, a proposed process for drugs targeting very small rare disease populations with significant unmet need and a known genetic defect; the Rare Disease Innovation Hub, which aims to increase collaboration across the FDA; and FDA’s framework for accelerating development of individualized therapies for ultra-rare diseases, a draft framework meant to support development and review of certain individualized therapies.
According to EveryLife, recent FDA activity includes three finalized patient-focused drug development guidances, five pilot programs to improve rare disease regulatory science, and 12 FDA initiatives. New guidance documents also address clinical trial design, real-world evidence, accelerated approval, and other topics relevant to rare disease therapy development.
FDA programs offer promise but challenges remain
While these tools provide opportunities to accelerate treatment development, EveryLife noted that questions remain about how consistently they can be understood, used, and applied across rare disease communities. During the workshop, participants discussed the growing complexity of the regulatory environment and how current pathways, guidance documents, and policy frameworks are being applied to rare disease therapy development.
The event also focused on finding ways to turn successful examples of drug development into practical, repeatable approaches that can be used more widely across different rare diseases. Participants also discussed ways to share scientific and regulatory knowledge more effectively, with the goal of making treatment reviews more consistent. The workshop also aimed to identify policy and legislative actions that could help address ongoing gaps and barriers.
The workshop discussions also aimed to help inform additions to the Guide to Patient Involvement in Rare Disease Therapy Development, a resource developed by EveryLife to help stakeholders incorporate patient experience data into therapy development and regulatory decision-making. Updates to the guide are intended to reflect new FDA programs, guidance documents, and emerging best practices. The goal is to help keep patient input credible, actionable, and aligned with current regulatory expectations.
